Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease
The FDA issued a CRL to the BLA of tabelecleucel in EBV+ PTLD following at least 1 prior line of treatment.
Related Articles
Durvalumab Shifts Decades Long SOC as First FDA-Approved Immunotherapy Regimen in LS-SCLC
Suresh Senan, MRCP, FRCR, PhD, details how the FDA approval of durvalumab has changed care for patients with limited-stage small cell lung cancer.
Sasanlimab Plus BCG Could Alter Treatment Paradigm in BCG-Naive, High-Risk NMIBC
Neal Shore, MD, FACS, discusses implications of data for sasanlimab plus BCG in BCG-naive, high-risk non–muscle-invasive bladder cancer.
Tisotumab Vedotin Boosts Survival in Chinese Subpopulation With Previously Treated Cervical Cancer
Tisotumab vedotin led to improved survival vs chemotherapy in a Chinese subpopulation of previously treated cervical cancer enrolled in innovaTV 301.
The Power & Reach of Social Media for Reliable Patient… : Oncology Times
An abstract is unavailable.
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology
Nature Reviews Clinical Oncology – Paediatric acute myeloid leukaemia (AML) highlights the challenges of drug development for rare diseases, in which limited patient numbers and…
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first…
EU/UK Approvals Sought for Nogapendekin Alfa Inbakicept Plus BCG in BCG-Unresponsive NMIBC With CIS
Nogapendekin alfa inbakicept MAAs have been submitted to the EU’s EMA and the UK’s MHRA for BCG-unresponsive non–muscle-invasive bladder cancer.
New institute musters forces against lethal skin cancer – UW Medicine | Newsroom
Media Contact: Brian Donohue – bdonohue@uw.edu, 206-543-7856 Dubbed “MC3,” the institute emerged with the restructuring of programs of patient care, training and research that straddle…
A Preview of Transformational Presentations at ASCO GI 2025
Sessions of interest at the 2025 Gastrointestinal Cancers Symposium will include data on colorectal cancer, pancreatic ductal adenocarcinoma, and more.
Addition of ASCT to Ibrutinib Plus Rituximab Does Not Confer Benefit in Lower-Risk, Younger MCL
Martin Dreyling, MD, PhD, discusses the role of ASCT with or without an ibrutinib-based regimen in younger patients with mantle cell lymphoma.